Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Hybridoma Technology01:31

Hybridoma Technology

14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Thickness-dependent surface reconstructions in non-van der Waals two-dimensional materials.

Physical chemistry chemical physics : PCCP·2024
Same author

Case report: Plasma exchange treatment in a patient with severe tetanus.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2024
Same author

KDM6B knockdown alleviates sleep deprivation-induced cerebrovascular lesions in APP/PS1 mice by inhibiting PARP16 expression.

Biochemical pharmacology·2024
Same author

Opportunities for System Neuroscience.

Advances in neurobiology·2024
Same author

The Role of Extracellular Vesicles Derived from MicroRNA-146a-modified Mesenchymal Stem Cells in Modulating Inflammation in Experimental Glenohumeral Osteoarthritis.

Iranian journal of allergy, asthma, and immunology·2024
Same author

HERB 2.0: an updated database integrating clinical and experimental evidence for traditional Chinese medicine.

Nucleic acids research·2024

相关实验视频

Updated: Jun 4, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

236

非亲和平台用于处理旋进入孔双特异抗体.

Xiaoyang Wang1, Min Li1, Mengting Li1

  • 1Shanghai AsymBio Biotechnology Co., Ltd, Building 8, No.12, Lane 855, Jinzheng Road, Jinshan Industrial Park, Shanghai, China.

Bioresources and bioprocessing
|December 18, 2024
PubMed
概括

这项研究引入了一种对双特异抗体的新,简化净化方法,实现高纯度和回收. 非蛋白质A平台为生物治疗开发提供了有竞争力的替代方案.

关键词:
双特异性抗体 双特异性抗体副产品 副产品 副产品这种类型的同类基因是同类基因.非蛋白质A净化过程

更多相关视频

High-throughput Protein Expression Generator Using a Microfluidic Platform
09:26

High-throughput Protein Expression Generator Using a Microfluidic Platform

Published on: August 23, 2012

11.7K
Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms
15:27

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms

Published on: April 17, 2017

20.7K

相关实验视频

Last Updated: Jun 4, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

236
High-throughput Protein Expression Generator Using a Microfluidic Platform
09:26

High-throughput Protein Expression Generator Using a Microfluidic Platform

Published on: August 23, 2012

11.7K
Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms
15:27

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms

Published on: April 17, 2017

20.7K

科学领域:

  • 生物化学 生化学
  • 生物技术是生物技术.
  • 蛋白质净化 蛋白质净化

背景情况:

  • 双特异性抗体提供治疗优势,但由于副产品的形成而面临发展挑战.
  • 高分子量和低分子量变体,以及同质体,使下游净化复杂化.
  • 副产品与点蛋白质具有相似的物理化学特性,这阻碍了有效的分离.

研究的目的:

  • 开发一种非蛋白质A净化平台,用于双特异性抗体.
  • 简化净化过程,克服与副产品清除相关的挑战.
  • 为传统的亲和色谱方法提供一个有竞争力的替代方案.

主要方法:

  • 采用了两步色谱方法,利用混合模式的Capto粘合树脂进行捕获.
  • 捕获步骤是在pH 7.90 ± 0.10.10下进行的.
  • 阳离子交换色谱作为抛光步骤来实现高纯度.

主要成果:

  • 净化方法通过大小排除高性能液态染色学 (SEC-HPLC) 产生了98%的最终产品纯度.
  • 反相高性能液态染色学 (RP-HPLC) 也证实了98%的纯度.
  • 剩余宿主细胞蛋白质被控制在10ppm,大约60%的恢复率.

结论:

  • 开发的非蛋白质A平台简化了双特异抗体净化.
  • 这种方法提供了一种简化且具有成本效益的替代传统蛋白质A亲和染色学.
  • 该平台展示了双特异抗体治疗药物的商业开发的巨大潜力.